Primary Myelofibrosis Clinical Trial
Official title:
Inrebic® (Fedratinib) Post-Marketing Surveillance in Korean Patients With Myelofibrosis
The purpose of this study is to assess the real-world safety of fedratinib for the treatment of adult participants with primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), or post essential thrombocythemia myelofibrosis (post-ET MF) who were previously treated with ruxolitinib. Participants will represent the overall patient population with PMF, post-PV MF or post-ET MF who lost adequate response to and/or are intolerant to ruxolitinib. Inadequate response definitions will follow Ministry of Food and Drug Safety-approved label and reimbursement criteria of the Health Insurance Review & Assessment Service.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01178281 -
Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence
|
Phase 3 | |
| Not yet recruiting |
NCT06327100 -
Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
|
Phase 2 | |
| Active, not recruiting |
NCT00095784 -
Decitabine in Treating Patients With Myelofibrosis
|
Phase 2 | |
| Recruiting |
NCT02897297 -
Myeloproliferative Neoplastic Diseases Observatory From Brest
|
||
| Terminated |
NCT02091752 -
A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)
|
Phase 2 | |
| Completed |
NCT01445769 -
Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis
|
Phase 2 | |
| Completed |
NCT01233921 -
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer
|
N/A | |
| Unknown status |
NCT01298934 -
LBH589 (Panobinostat) for the Treatment of Myelofibrosis
|
Phase 1/Phase 2 | |
| Terminated |
NCT00387426 -
Sunitinib in Treating Patients With Idiopathic Myelofibrosis
|
Phase 2 | |
| Completed |
NCT05044026 -
A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With Myelofibrosis
|
||
| Active, not recruiting |
NCT03952039 -
An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
|
Phase 3 | |
| Active, not recruiting |
NCT02530619 -
Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia
|
N/A | |
| Completed |
NCT01588015 -
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
|
Phase 1 | |
| Completed |
NCT01731951 -
Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis
|
Phase 2 | |
| Completed |
NCT01371617 -
A Phase 2 Study With IPI-926 in Patients With Myelofibrosis
|
Phase 2 | |
| Active, not recruiting |
NCT02251821 -
JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis
|
Phase 2 | |
| Active, not recruiting |
NCT04446650 -
A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
|
Phase 1/Phase 2 | |
| Completed |
NCT01981850 -
A Phase 2 Study of RO7490677 In Participants With Myelofibrosis
|
Phase 2 | |
| Withdrawn |
NCT04283526 -
Study of Select Combinations in Adults With Myelofibrosis
|
Phase 1 | |
| Withdrawn |
NCT02584777 -
A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis
|
Phase 2 |